Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by grosdavidon May 03, 2020 11:26pm

286 Views

Post# 30982181

AGN is a winner

Good posts shared this weekend. Happy to see Algernon show up on the Health Canada list. I know it was approved on Wednesday, but its always nice to see it appear on a site like Health Canada.

I've checked the other on the list, like someone mentioned Remdisivr, Hydroxychloroquine. Out of 18 on the list that have information regarding the clinical trials, I've counted :

- 6 using Hydroxychloroquine, which from the last update I've read, caused more death than help...
- 5-6 in phase 2 or lower (I would be counting more if the newly approved on the list had their link to the clinical trial).
- Many of them have ridiculous end of completion date in Feb-April 2021...it is quite long for Phase 2 and 3. This is advantegeous for AGN.

Thanks
David

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario